Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
06 nov. 2023 13h07 HE
|
Sobi, Inc.
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
Doptelet (Avatrombopag): A 2nd Generation, Once Daily, Orally Administered TPO Receptor Agonist Approved for the Treatment of Thrombocytopenia - Global Drug Insight and Market Forecast 2017-2030
30 déc. 2020 08h48 HE
|
Research and Markets
Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Doptelet (Avatrombopag) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Doptelet (avatrombopag)...